Analysis of therapeutic effect and safety of target-dose metoprolol in the treatment of patients with diabetes mellitus with chronic heart failure

Objective: to explore the therapeutic effect and safety of target-dose metoprolol in treating chronic heart failure (chf) patients complicated with diabetes mellitus (dm). methods: one hundred and fifty-four elderly patients were randomly divided into an observation group and a control group (n=77), which were treated with target-dose metoprolol and conventional therapy, and routinely treated respectively. the new york heart association (nyha) classification, left ventricular end-systolic diameter (lvesd), left ventricular end-diastolic diameter (lvedd), left ventricular ejection fraction (lvef), 6-min walking distance and medication safety of the two groups were compared. results: compared with the results before treatment, the nyha classification, lvesd, lvedd, lvef and 6-minutes walking distance of both groups were significantly improved (p < 0.05), with significantly better results in the observation group than those in the control group after treatment (p < 0.05). in the 6 months of follow-up, the incidence of cardiac events in the observation group (3.90%) was significantly lower than that of the control group (14.29%) (p < 0.05). the levels of average fasting blood sugar and glycosylated hemoglobin in the groups showed no significant differences (p > 0.05). conclusion: treating chf patients complicated with dm with target-dose metoprolol can obviously boost the cardiac function and exercise tolerance, leading to satisfactory clinical therapeutic effect, high security and moderate tolerance.